The United Kingdom and the United States have announced a key trade agreement that will preserve zero levies on British pharmaceutical products being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost funding on drugs through the National Health Service (NHS). This commitment secures that import taxes on these crucial products will stay at nothing for a duration of three years.
This development is in response to previous statements to hike import taxes on patented drug products, with figures floated reaching 100%.
"This arrangement with the UK strengthens the worldwide climate for cutting-edge drugs and brings much-needed fairness to U.S.–U.K. drug exports," an announcement declared.
Economic Importance
Drugs are one of the UK's most significant export categories to the United States, which is easily the biggest market for leading companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period to the end of the third quarter, the UK sold pharmaceutical products worth billions to the US. This value represented 17.4% of British export trade in that period.
"This guarantee safeguards work, stimulates investment and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Detailed UK Commitments
The agreement entails several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to double overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at 15%. Previously, rebates were more than 20%.
Broader Context
This agreement follows a ongoing dispute between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
The disagreement were heightened by assertions that American consumers were paying a premium for the equivalent treatments than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the previous ten-year period.
